Novo Nordisk's Amycretin Shows Strong Weight-Loss Results in Trial

Novo Nordisk’s obesity drug amycretin delivered a major boost to the company today, after new mid-stage trial results showed the treatment helped patients with type 2 diabetes lose up to 14.5% of their weight in 36 weeks.

The update quickly lifted the drugmaker’s Denmark-listed shares by 3.3%, signaling strong confidence from investors.

The company said amycretin appeared safe and well tolerated, with most patients experiencing only mild to moderate gastrointestinal effects.

With these results in hand, Novo Nordisk plans to move the drug into late-stage trials in 2026, marking another step in the intensifying race within the global obesity-drug market.

Also Read: Oral GLP-1 Drugs: Expanding Patient Access in Obesity and Diabetes Care

Amycretin is positioned as Novo’s next-generation obesity treatment, designed with a dual-action mechanism that targets both GLP-1, a key gut hormone, and amylin, a pancreatic hormone involved in appetite and glucose control. This combination could give the therapy an edge as demand for advanced metabolic treatments continues to surge worldwide.

The company said the findings strengthen its belief in the drug’s potential. “The data further validates the potential best-in-class profile of amycretin,” said Martin Holst Lange, chief scientific officer and executive vice president of research and development at Novo Nordisk.

For an industry already transformed by modern weight-loss medicines, the progress of the Novo Nordisk obesity drug amycretin signals what could be the next major chapter. Strong early results, a clear development timeline, and growing market attention suggest this candidate may soon stand among the most closely watched treatments in the field.